Contact Us
Drug Search Results
More Filters [+]

RO-5083945

Alternative Names: ro-5083945, ro5083945, ro 5083945
Latest Update: 2016-11-04
Latest Update Note: Clinical Trial Update

Product Description

RO5083945 is a glycoengineered anti EGFR IgG1 mAb exhibiting increased binding affinity for all Fc_RIIIa variants expressed on immune effector cells.

Mechanisms of Action: EGFR Antagonist

Novel Mechanism: No

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for RO-5083945

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Colorectal Cancer|Squamous Cell Carcinoma|Non-Small-Cell Lung Cancer|Sarcoma

Phase 1: Squamous Cell Carcinoma|Non-Small-Cell Lung Cancer|Head and Neck Cancer|Colorectal Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
BP28577

P1

Withdrawn

Squamous Cell Carcinoma|Non-Small-Cell Lung Cancer

2016-02-01

2010-022983-11

P2

Terminated

Colorectal Cancer

2013-12-19

BP25438

P2

Completed

Colorectal Cancer

2013-12-01

45%
2010-018945-72

P2

Completed

Non-Small-Cell Lung Cancer

2013-07-30

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions